# A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

> **NCT01303796** · PHASE3 · COMPLETED · sponsor: **Cyclacel Pharmaceuticals, Inc.** · enrollment: 482 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Sapacitabine
- **DRUG:** Decitabine

## Key facts

- **NCT ID:** NCT01303796
- **Lead sponsor:** Cyclacel Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10-01
- **Primary completion:** 2016-12-15
- **Final completion:** 2017-07-31
- **Target enrollment:** 482 (ACTUAL)
- **Last updated:** 2022-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01303796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01303796, "A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT01303796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*